Short answer
VERACYTE, INC. (VCYT) filed an 8-K current report with the SEC on September 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure). Veracyte acquired Convergent Genomics, adding UroAmp and urine tumor DNA technology for bladder cancer diagnostics.
VERACYTE, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Veracyte acquired Convergent Genomics, adding UroAmp and urine tumor DNA technology for bladder cancer diagnostics
- $150 million upfront cash consideration, subject to customary purchase price adjustments
- Up to $30 million additional cash tied to UroAmp publication and reimbursement milestones
- Convergent becomes a wholly owned subsidiary, expanding Veracyte’s diagnostic pipeline and commercialization obligations
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Veracyte completed its acquisition of Convergent on September 14, 2026
- Transaction advances Veracyte’s strategic expansion through Convergent’s acquired assets
- Merger Agreement terms govern the completed transaction and related obligations
Item 7.01 · Regulation FD Disclosure
- Veracyte completed its acquisition of Convergent on September 14, 2026
- Transaction signals expansion through Convergent, with strategic and financial details in Exhibit 99.1
- Exhibit 99.1 contains the press release furnished under Regulation FD and incorporated by reference
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other VERACYTE, INC. 8-K filings
Get the next VCYT 8-K as it lands
Follow VCYT for push alerts, or ask the research agent what this filing means.